We recently compiled a list of the 12 Best Stocks to Buy and Hold For 10 Years. In this article, we are going to take a look ...

The phase 3b STEP UP trial in more than 1,400 patients compared a 7.2mg weekly subcutaneous injection of semaglutide to the standard 2.6mg weekly dose sold as Wegovy or a matched placebo.

When the stock market experiences a sharp decline, as it did after the Trump administration announced tariffs on its trade partners and China responded with retaliatory tariffs, many investors start ...

Ozempic came out with a higher-strength, 2 mg dose that was not approved until ... Novo Nordisk went ahead and branded their weight-loss product as Wegovy. It’s still Ozempic, but it’s branded ...

Effective July 1, 2025, CVS Caremark will place Wegovy injection 2.4 mg as preferred on its commercial template formularies.

A decision is expected in the fourth quarter of 2025.

Novo Nordisk (NVO) stock in focus as oral Wegovy is accepted for FDA review for chronic weight management. Read more here.

A late-stage clinical study showed that this weight loss drug helped 2 out of 3 people with the life-threatening liver ...

Starting July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial template ...

A batch of the drug is under a limited voluntary recall after a shipping error exposed certain doses to improper temperatures.

The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...